AzTrials
AzTrials

Venous Stasis UlcerPhase 4NCT00534937

Flexitouch Compression System for Venous Stasis Ulcer

A Phase 4 study testing Compression wrapping and Flexitouch compression pump in people with Venous Stasis Ulcer, run by West Penn Allegheny Health System at 2 sites in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The researchers hypothesize that utilization of the Flexitouch system will improve the healing rates of (venous stasis ulcers) VSU compared to traditional compression wrapping therapy alone. Read more about this study

Who is it for?
Ages 18 to 90 years
Conditions the study is for
Venous Stasis Ulcer
What is being tested?
Compression wrapping and Flexitouch compression pump
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
89 participants
Where
2 sitesUnited States
Study dates
Sep 2007to Dec 2010
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 90 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • This study will enroll patients in a prospective manner with chronic venous insufficiency and venous stasis ulceration as determined from clinical presentation, positive venous reflux testing, or both.
  • Patients must be 18 years old or more.
  • The VSU size must be in the range 1-64 cm2.
  • The ulcer must extend through both the epidermis and dermis, with no exposed tendon or bone.
  • The VSU must have been present for more than 1 month.
  • The ulcer must be located between and including the knee and ankle.
  • The wound bed must have viable tissues with granulation tissue.

Who cannot join

  • Exposed bone, tendon, or fascia.
  • Severe rheumatoid arthritis.
  • History of radiotherapy to the ulcer site.
  • Uncontrolled congestive heart failure.
  • Receiving corticosteroids or immune suppressives.
  • History of collagen vascular disease.
Show all 22Show fewer
  • Known malnutrition (albumin < 2.5 g/dL). If malnutrition is suspected by the principal investigator, the albumin level should be checked to determine whether the patient meets the albumin criterion.
  • Ulcer clinically infected at the time of entry into the study. However, patients may be entered into the study after successful treatment of infection.
  • Known uncontrolled diabetes (HgbA1c > 12%). If the principal investigator suspects uncontrolled diabetes, the Hgb A1c should be checked to determine patient eligibility.
  • Signs of cellulitis, osteomyelitis, or necrotic or avascular ulcer bed(s).
  • Known arterial insufficiency (Ankle-brachial index < 0.7, or TCPO2 < 35 mmHg, or Toe brachial index < 0.4). If the principal investigator suspects uncontrolled diabetes, the Ankle-brachial index should be checked to determine patient eligibility.
  • Active sickle cell disease.
  • Unable to comply with the procedures described in the protocol.
  • Enrolled in a clinical evaluation for another investigational wound-care device or drug.
  • Patients diagnosed with deep venous thrombosis or phlebitis in the affected limb in the last 6 months.
  • Pregnancy, suspected or confirmed.
  • History of peripheral vascular disease, or chronic renal disease.
  • Known active or recurrent cancer, or currently receiving chemotherapy or radiation therapy.
  • History of pulmonary embolism.
  • Poorly controlled asthma.
  • Use of Apligraf, skin graft or similar biological dressing within 30 days of study entry.
  • Patients with concurrent atrophie blanche.

Trial locations and contacts

2 sites in 1 country.

United States2 sites
  • Cleveland Clinic

    Cleveland, Ohio, 44195

  • Allegheny General Hospital Advanced Wound Healing and Lymphedema Center

    Pittsburgh, Pennsylvania, 15212

Other trials in United States

About this study

Official title: A Randomized Trial of the Flexitouch Compression System as an Adjunctive Treatment for Venous Stasis Ulcer

The researchers hypothesize that utilization of the Flexitouch system will improve the healing rates of (venous stasis ulcers) VSU compared to traditional compression wrapping therapy alone.

Primary Objective: The primary study objective is to determine whether the complete healing rate of venous stasis ulcers at 12 weeks is improved by the addition of Flexitouch® System compression therapy to a standard regimen of compression wrapping.

Read more

Secondary Objectives:

  • To determine whether the addition of Flexitouch System compression therapy to a standard regimen of compression wrapping increases the percentage reduction in wound surface area.
  • To determine whether the addition of Flexitouch compression therapy to a standard regimen of compression wrapping increases the percentage reduction in volume of the affected limb.
  • To determine whether the addition of Flexitouch compression therapy to a standard regimen of compression wrapping decreases the time to healing of the venous stasis ulcer.
Read the detailed description

Background:

Overview of venous stasis ulcers (1-3): Venous stasis ulceration is a common complication of venous insufficiency in the United States. Venous stasis ulcers (VSU) are associated with very significant morbidity, including patient disability, moderate to severe pain, and frequent leg infections. There is also a large cost associated with the medical care needed for this condition and the inability of patients to work. In some patients, this condition can be life- or limb-threatening.

Current standard of care for VSU: It is widely accepted that VSU should be treated by an individualized program of compression wrapping therapy (3-5). This therapy is designed to counteract the presumed pathophysiology of VSU, which develop as a result of valvular reflux and venous hypertension. However, the efficacy of compression therapy alone is suboptimal, with healing rates of roughly 34% reported after 12 weeks of therapy (6). Various adjunctive treatments have been studied, including artificial skin grafts (6-8). However, none of these adjunctive modalities have become widely accepted for the treatment of VSU.

Potential role of compression pumps: Intermittent sequential compression pumps are widely used as an adjunctive modality in the treatment of VSU. These pumps use high compression and are expensive, but this expense may be outweighed by improved healing of VSU. The use of compression pumps is consistent with the pathophysiology of VSU, but data regarding the efficacy of such therapy is scarce. To date, no study has adequately assessed the efficacy of compression pump therapy in the treatment of VSU (9).

Flexitouch System: The Flexitouch System was designed by a therapist trained in manual lymphatic drainage therapy and is produced by Tactile Systems Technology, Inc. The Flexitouch System was designed to simulate MLD techniques and is intended for home use during the self-management phase of CDT. MLD is one (of four) component(s) of Complete Decongestive Therapy, considered the "Gold Standard" for treatment of lymphedema. MLD is a gentle, manual technique producing very light directional pressure/stretch on the skin with manipulation of healthy lymph nodes and vessels. The effects of properly applied MLD include increased intake of lymphatic loads into the lymphatic system, increased lymphangiomotoricity, increased volume of transported lymph fluid, increased venous return in the superficial venous system, promotion of parasympathetic response and pain control. Treatment is always initiated at the trunk segments, with decongestion of proximal areas, prior to addressing the involved extremity (to clear central areas and promote decongestion of more distal areas). The extremity is then treated in segments, starting with the proximal segments and then progressing from distal to proximal regions. The Flexitouch® System is not intended to replace the intensive phase of CDT. However, it follows the principles of MLD in many ways. Flexitouch system provides limb treatment, but in addition, it addresses trunk congestion. The lower extremity garment set consists of two garments, one garment fits over the affected lower extremity and the other fits over the lower abdomen/trunk. Each garment is made up of multiple inflatable chambers within a flexible, stretchable fabric. The treatment consists of a 2-phase program. As in MLD, the preparation phase begins the treatment starting at the inguinal quadrant. Each curved trunk chamber inflates and deflates sequentially to facilitate the movement of edema fluid into the systemic circulation. The cycle is repeated several times. The inflation/deflation cycle is then repeated in each limb region from the knee to the groin, from the ankle to the knee, and finally from the toes to the ankle. The second phase, drainage, begins the sequential inflation/deflation cycle at the toes and continues moving up the leg to the quadrant of the trunk to facilitate the movement of edema fluid from the inguinal quadrant into the system circulation.

Choice of compression pump device for study of VSU treatment: A variety of inflatable compression pumps are available, but there are no data to help choose among these devices (9). No compression device is accepted as a standard of care for VSU. Flexitouch system differs from standard (intermittent sequential) compression pumps in significant ways. As described above, Flexitouch system is unique as a compression device, because it provides not only sequential limb compression, but also trunk compression. Flexitouch system's two-phase program (preparation and drainage) also makes it different from other compression devices. The fact that the system was created for lymphedema may be an advantage in the treatment of VSU, because many authors (10;11) believe that secondary lymphedema plays an important role among VSU patients.

Study Outline:

Patient enrollment procedure

  • An approved consent form and authorization permitting release of personal health information must be signed by the patient or guardian.
  • All eligibility requirements indicated in Section 3.0 must be satisfied.
  • The patient must be registered by calling the study coordinator Lisa Rudman, at Allegheny General Hospital (412-359-4325).

General treatment plan: After enrollment, all patients will be seen once per week for a 12-week period for standard compression wrapping. At each visit, treatment and assessment will be undertaken as described below. The Flexitouch group only will use the Flexitouch System both at home (once daily) and in-clinic (once per week).

Essential elements of treatment and assessment:

Applicable to ALL patients

  • The patients will be seen at the wound center one(1) times per week for 12 weeks.
  • Patients will receive compression wrapping as standard of care therapy. The precise amount of compression will be individualized according to patient tolerance using 3M Coban 2 layer Compression System.
  • The wound area will be measured and photographed weekly, using wound tracing and planimetry software.
  • The limb volume will be measured weekly, using available software (NetHealth, Pittsburgh PA).
  • The presence or absence of wound infection will be assessed. The need for wound debridement will be recorded.
  • The wound will be scored as to whether or not it has healed. If the wound healed at a previous visit, the presence of recurrent ulceration will be assessed.
  • The occurrence of treatment failure will be recorded (see section 7d).
  • Comprehensive standard wound care treatment including gentle wound cleansing with saline solution at each visit, maintaining moisture balance in the wound and periwound with appropriate dressings (alginate, foam, hydrogel or hydrocolloid), reminding subjects of the importance of proper nutrition, leg elevation at rest and activity, including frequent ambulation and ankle ROM exercises through the day.

Additional steps applicable to patients randomized to Flexitouch arm:

  • Patients will be provided a home Flexitouch unit. They will be given instructions to use the Flexitouch system on a once daily basis. They will not need remove the compression wrap for the home therapy.
  • In addition to the home use, at each clinic visit, the patient's trunk and affected limb will be treated for 60 minutes with the Flexitouch system.
  • The patient will be asked to indicate their level of comfort with the in-clinic Flexitouch session (scale of 0 to 5; 0 = very comfortable, 5 = very uncomfortable).
Being tested
Compression wrapping, Flexitouch compression pump
Keywords
Venous stasis ulcer, Compression pump, Randomized trial, Flexitouch compression
Medical subject headings
Varicose Ulcer

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Compression wrappingProcedure or surgery

    Also called 3M short-stretch compression wrap

    Short-stretch compression wrap will be applied at least once a week.

  • Flexitouch compression pumpProcedure or surgery

    Also called 3M compression wrap

    In addition to short-stretch wrapping, this group will received once-daily Flexitouch compression pump, both at home and during the once-a-week clinic visits.

Study groups in NCT00534937
Study groupRoleWhat they receive
Standard compressionActive comparatorPatients in this arm will receive current standard of care (once-weekly short-stretch compression wrapping).
Receives: Procedure: Compression wrapping
FlexitouchExperimentalPatients in this arm will receive once-a-week short stretch compression wrapping AND once-daily Flexitouch pump application (including Flexitouch application once-a-week in the clinic setting).
Receives: Procedure: Flexitouch compression pump

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Complete Healing Rate of Venous Stasis Ulcers

    Number of subjects that experience complete healing of the study venous stasis ulcer during the 12 week treatment period.

    Measured: 12 weeks

Secondary outcomes (3)
  1. Change in Wound Surface Area for Non Healed Subject at 12 Weeks.

    Change in wound surface area in cm2 from the initial screening to week 12 for all subject who did not completely healed before or at the 12 week visit.

    Measured: 12 weeks

  2. Percentage Change in Volume of the Affected Limb (-Reduction; +Increase)

    Measured: 12 weeks

  3. Time to Healing of the Venous Stasis Ulcer

    Only 2 time points so no calculation details are necessary. The change is calculated as the later time point minus the earlier time point (e.g., 12 weeks minus baseline).

    Measured: Baseline to 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Sep 2007 (estimated)
  2. Study startSep 2007
  3. Primary completionJul 2010
  4. Study completionDec 2010

Why it stopped: Ineffective Recruitment (Business Decision)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
89 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00534937
Sponsor's protocol ID
RC-4372
Status last verified
Jan 2013
First submitted
24 Sep 2007
Last updated
1 Mar 2013
Data monitoring committee
Yes

Publications

  • Palfreyman SJ, Nelson EA, Lochiel R, Michaels JA. Dressings for healing venous leg ulcers. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001103. doi: 10.1002/14651858.CD001103.pub2.

    PubMed 16855958
  • Pascarella L, Schonbein GW, Bergan JJ. Microcirculation and venous ulcers: a review. Ann Vasc Surg. 2005 Nov;19(6):921-7. doi: 10.1007/s10016-005-7661-3.

    PubMed 16247708
  • Black SB. Venous stasis ulcers: a review. Ostomy Wound Manage. 1995 Sep;41(8):20-2, 24-6, 28-30 passim.

    PubMed 7546118
  • Kramer SA. Compression wraps for venous ulcer healing: a review. J Vasc Nurs. 1999 Dec;17(4):89-97; quiz 98-9. doi: 10.1016/s1062-0303(99)90034-1.

    PubMed 10818887
  • Hansson C. Optimal treatment of venous (stasis) ulcers in elderly patients. Drugs Aging. 1994 Nov;5(5):323-34. doi: 10.2165/00002512-199405050-00002.

    PubMed 7833586
  • Mostow EN, Haraway GD, Dalsing M, Hodde JP, King D; OASIS Venus Ulcer Study Group. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. J Vasc Surg. 2005 May;41(5):837-43. doi: 10.1016/j.jvs.2005.01.042.

    PubMed 15886669
  • O'Donnell TF Jr, Lau J. A systematic review of randomized controlled trials of wound dressings for chronic venous ulcer. J Vasc Surg. 2006 Nov;44(5):1118-25. doi: 10.1016/j.jvs.2006.08.004.

    PubMed 17098555
  • Falanga V, Sabolinski M. A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen. 1999 Jul-Aug;7(4):201-7. doi: 10.1046/j.1524-475x.1999.00201.x.

    PubMed 10781211
  • Berliner E, Ozbilgin B, Zarin DA. A systematic review of pneumatic compression for treatment of chronic venous insufficiency and venous ulcers. J Vasc Surg. 2003 Mar;37(3):539-44. doi: 10.1067/mva.2003.103.

    PubMed 12618689
  • Wollina U, Abdel-Naser MB, Mani R. A review of the microcirculation in skin in patients with chronic venous insufficiency: the problem and the evidence available for therapeutic options. Int J Low Extrem Wounds. 2006 Sep;5(3):169-80. doi: 10.1177/1534734606291870.

    PubMed 16928673
  • Felty CL, Rooke TW. Compression therapy for chronic venous insufficiency. Semin Vasc Surg. 2005 Mar;18(1):36-40. doi: 10.1053/j.semvascsurg.2004.12.010.

    PubMed 15791552

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Compression wrapping and Flexitouch compression pump in people with Venous Stasis Ulcer, run by West Penn Allegheny Health System at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 1 Mar 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 1 Mar 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Complete Healing Rate of Venous Stasis Ulcers (time frame: 12 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00534937, which also lists 11 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Mar 2013.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in